3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
11
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Sarcoma
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Interventions
Leucovorin
38
Fluorouracil
36
Oxaliplatin
34
Bevacizumab
34
Irinotecan
32
Cetuximab
23
Capecitabine
18
Panitumumab
14
IFL protocol
7
Folfox protocol
6
Celecoxib
6
Radiotherapy
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gene Expression Profiling
5
regorafenib
4
pembrolizumab
4
dehydroftorafur
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
aflibercept
3
Surgical Procedures, Operative
3
Sorafenib
3
Radiosurgery
3
Ipilimumab
3
Gemcitabine
3
Fentanyl
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Colonic Neoplasms
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts